Peptide-based vectors for therapeutic delivery

  • Research
  • Team
  • Publications
  • More...

Our group “Peptide-based vectors for therapeutic delivery” is interested in the design of pharmacological peptides that alter the intracellular protein-protein interactions (PPIs) in various physiological and pathological conditions.

Our group also specializes in the design of peptide-based delivery systems (cell-penetrating peptides) for the intracellular release of pharmacological PPI-interfering peptides and also of other therapeutic molecules, such as oligonucleotides or active compounds.

Our activities involve the design of peptides (screening of peptide libraries by SPOT synthesis and peptide synthesis), the characterization of nanoparticles (by biophysical techniques) and the study of their biological activity in vitro, in cellulo and in vivo.

The applications of our pharmacological molecules are focused on human diseases, such as myocardial infarction, cystic fibrosis and cancer.

Contact our team

Replace the name and address below with that of the member to contact

Prisca Boisguerin

Members of the team

  • Maryam ATOUF
    (Trainee) +33 (0)4 34 35 95 27
  • Prisca BOISGUERIN Group Leader
    (Staff Scientist) +33 (0)4 34 35 95 26
  • Berangere CHAVEY
    (Trainee) +33 (0)4 34 35 95 27
  • Sebastien DESHAYES
    (Staff Scientist) +33 (0)4 34 35 95 27
  • Etienne DUPRE
    (Trainee) +33 (0)4 34 35 95 26
  • Marion DUSSOT
    (Research Assistant) +33 (0)4 34 35 95 27
  • Karidia KONATE
    (Research Assistant) +33 (0)4 34 35 95 27
  • Nizar NASR
    (Trainee) +33 (0)4 34 35 95 26
  • Francois PELLETIER
    (Trainee) +33 (0)4 34 35 95 26
  • Eric VIVES
    (Staff Scientist) +33 (0)4 34 35 95 26
    • 2018

      PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28γ.

      Jonik-Nowak B, Menneteau T, Fesquet D, Baldin V, Bonne-Andrea C, Méchali F, Fabre B, Boisguerin P, de Rossi S, Henriquet[...]

      Proc Natl Acad Sci U S A. pii: 201722299. Pubmed

    • 2017

      Optimization of the process of inverted peptides (PIPEPLUS) to screen PDZ domain ligands.

      Seisel Q, Rädisch M, Gill NP, Madden DR, Boisguerin P.

      Bioorg Med Chem Lett. 27(14):3111-3116. Pubmed

    • 2017

      Endogenous and Exogenous KdpF Peptide Increases Susceptibility of Mycobacterium bovis BCG to Nitrosative Stress and Reduces Intramacrophage Replication.

      Rosas Olvera M, Vivès E, Molle V, Blanc-Potard AB, Gannoun-Zaki L.

      Front Cell Infect Microbiol. 7:115. Pubmed

    • 2017

      A retro-inverso cell-penetrating peptide for siRNA delivery.

      Vaissière A, Aldrian G, Konate K, Lindberg MF, Jourdan C, Telmar A, Seisel Q, Fernandez F, Viguier V, Genevois C,[...]

      J Nanobiotechnology. 15:34. Pubmed

    • 2017

      Cardiac mGluR1 metabotropic receptors in cardioprotection.

      Vincent A, Sportouch C, Covinhes A, Barrère C, Gallot L, Delgado-Betancourt V, Lattuca B, Solecki K, Boisguérin P, Piot C,[...]

      Cardiovasc Res. Pubmed

    • 2017

      PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo.

      Aldrian G, Vaissière A, Konate K, Seisel Q, Vivès E, Fernandez F, Viguier V, Genevois C, Couillaud F, Démèné H,[...]

      J Control Release. 256:79-91. Pubmed

    • 2015

      In Vitro Assays to Assess Exon Skipping in Duchenne Muscular Dystrophy.

      Boisguerin P, O'Donovan L, Gait MJ, Lebleu B.

      Methods Mol Biol. 1324:317-29. Pubmed

    • 2016

      Use of the Salmonella MgtR peptide as an antagonist of the Mycobacterium MgtC virulence factor.

      Belon C, Rosas Olvera M, Vives E, Kremer L, Gannoun-Zaki L, Blanc-Potard AB.

      Future Microbiol. 11(2):215-25. Pubmed

    • 2016

      Optimisation of vectorisation property: A comparative study for a secondary amphipathic peptide.

      Konate K, Lindberg MF, Vaissiere A, Jourdan C, Aldrian G, Margeat E, Deshayes S, Boisguerin P.

      Int J Pharm. 509:71-84. Pubmed

    • 2015

      In Vitro Assays to Assess Exon Skipping in Duchenne Muscular Dystrophy.

      Boisguerin P, O'Donovan L, Gait MJ, Lebleu B

      Methods Mol Biol. 1324:317-29. Pubmed

    • 2015

      Delivery of therapeutic oligonucleotides with cell penetrating peptides.

      Boisguérin P, Deshayes S, Gait MJ, O'Donovan L, Godfrey C, Betts CA, Wood MJ, Lebleu B.

      Adv Drug Deliv Rev. 87:52-67. Pubmed

    • 2014

      Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells.

      Lehto T, Castillo Alvarez A, Gauck S, Gait MJ, Coursindel T, Wood MJ, Lebleu B, Boisguerin P.

      Nucleic Acids Res. 42:3207-17. Pubmed

    • 2014

      Stereochemical preferences modulate affinity and selectivity among five PDZ domains that bind CFTR: comparative structural and sequence analyses.

      Amacher JF, Cushing PR, Brooks L, Boisguerin P, Madden DR.

      Structure. 22:82-93. Pubmed

    • 2013

      Fluorescence technologies for monitoring interactions between biological molecules in vitro.

      Deshayes S, Divita G.

      Prog Mol Biol Transl Sci. 113:109-43. Pubmed

    • 2013

      Modeling of non-covalent complexes of the cell-penetrating peptide CADY and its siRNA cargo.

      Crowet JM, Lins L, Deshayes S, Divita G, Morris M, Brasseur R, Thomas A.

      Biochim Biophys Acta. 1828(2):499-509. Pubmed

    • 2013

      Everything you always wanted to know about CADY-mediated siRNA delivery* (* but afraid to ask).

      Konate K, Rydstrom A, Divita G, Deshayes S.

      Curr Pharm Des. 19(16):2869-77. Pubmed

    • 2012

      Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines.

      Deshayes S, Konate K, Rydström A, Crombez L, Godefroy C, Milhiet PE, Thomas A, Brasseur R, Aldrian G, Heitz F,[...]

      Small. 8(14):2184-8. Pubmed

    • 2011

      UA62784 Is a cytotoxic inhibitor of microtubules, not CENP-E.

      Tcherniuk S, Deshayes S, Sarli V, Divita G, Abrieu A.

      Chem Biol. 18(5):631-41. Pubmed

    • 2011

      Interactions of amphipathic CPPs with model membranes.

      Deshayes S, Konate K, Aldrian G, Heitz F, Divita G.

      Methods Mol Biol. 2011;683:41-56. Pubmed

    • 2011

      Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles.

      Rydström A, Deshayes S, Konate K, Crombez L, Padari K, Boukhaddaoui H, Aldrian G, Pooga M, Divita G.

      PLoS One. 6(10):e25924. Pubmed

    • 2010

      Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery.

      Konate K, Crombez L, Deshayes S, Decaffmeyer M, Thomas A, Brasseur R, Aldrian G, Heitz F, Divita G.

      Biochemistry. 49(16):3393-402. Pubmed

    • 2010

      Secondary structure of cell-penetrating peptides controls membrane interaction and insertion.

      Eiríksdóttir E, Konate K, Langel U, Divita G, Deshayes S.

      Biochim Biophys Acta. 1798(6):1119-28. Pubmed

    • 2009

      Mechanism for HIV-1 Tat insertion into the endosome membrane.

      Yezid H, Konate K, Debaisieux S, Bonhoure A, Beaumelle B.

      J Biol Chem. 284(34):22736-46. Pubmed

    • 2008

      Structural polymorphism of two CPP: an important parameter of activity.

      Deshayes S, Decaffmeyer M, Brasseur R, Thomas A.

      Biochim Biophys Acta. 1778(5):1197-205. Pubmed

    • 2008

      Cell-penetrating peptides: from molecular mechanisms to therapeutics.

      Morris MC, Deshayes S, Heitz F, Divita G.

      Biol Cell. 100(4):201-17. Pubmed

    • 2008

      Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy.

      Deshayes S, Morris M, Heitz F, Divita G.

      Adv Drug Deliv Rev. 60(4-5):537-47. Pubmed

    • 2008

      Peptide-based nanoparticle for ex vivo and in vivo drug delivery.

      Crombez L, Morris MC, Deshayes S, Heitz F, Divita G.

      Curr Pharm Des. 14(34):3656-65. Pubmed